MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
14.15
+0.06 (0.43%)
Oct 14, 2025, 4:00 PM EDT - Market closed
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
64.00M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
INKT News
- 15 days ago - MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors - GlobeNewsWire
- 19 days ago - MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA - GlobeNewsWire
- 26 days ago - MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development - GlobeNewsWire
- 2 months ago - MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results - GlobeNewsWire
- 2 months ago - MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report - GlobeNewsWire
- 3 months ago - MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy - GlobeNewsWire
- 3 months ago - Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday? - Benzinga